Industries
Pharma & Life Sciences
For the Head of Portfolio, the Chief Medical Officer, and the Head of Regulatory Affairs in pharmaceutical organisations where every go/no-go decision — at a Stage Gate, a DSMB, or a submission-readiness review — will eventually be inspected.
21 CFR 11
FDA requires full decision audit trails
$2.6B
Average cost to bring a drug to market
45%
Of advancement decisions lack formal governance
"The regulatory question is never what you decided — it's why you decided it, and whether you would decide the same way again."
The Solution
How
helps pharma organizations
Portfolio advancement you can defend
Every stage-gate decision — advance, hold, terminate — compiled from the governance framework, evidenced by the data that triggered it, and traceable at inspection.
Clinical-trial governance at the DSMB moment
Efficacy thresholds, futility boundaries, safety-stopping rules — compiled from the protocol and enforced on the interim data. The DSMB minutes write themselves.
Submission readiness, certified before you file
Juris compiles the FDA guidance and your internal readiness criteria into an executable checklist and tells you, with evidence, which sections are ready and which are not.
From implicit expertise to certified logic
doesn't replace scientific judgment—it captures and certifies the logic that judgment produces, so every decision can be explained when scrutiny arrives.
Ready to certify your decision logic?
See how
helps pharma organizations preserve and defend their most critical decisions.